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ApoptosisStatins are drugs that lower blood cholesterol levels and reduce cardiovascularmorbidity andmortality. They are
generally well-tolerated, but myopathy is a potentially severe adverse reaction of these compounds. The mech-
anisms by which statins induce myotoxicity are not completely understood, but may be related to inhibition of
the AKT signaling pathway. The current studies were performed to explore the down-stream effects of the
statin-associated inhibition of AKT within the AKT signaling pathway and on myocyte biology and morphology
in C2C12myotubes and inmice in vivo.We exposed C2C12myotubes to 10 μMor 50 μMsimvastatin, atorvastatin
or rosuvastatin for 24 h. Simvastatin and atorvastatin inhibited AKT phosphorylation andwere cytotoxic starting
at 10 μM,whereas similar effectswere observed for rosuvastatin at 50 μM. Inhibition of AKT phosphorylationwas
associated with impaired phosphorylation of S6 kinase, ribosomal protein S6, 4E-binding protein 1 and FoxO3a,
resulting in reduced protein synthesis, accelerated myoﬁbrillar degradation and atrophy of C2C12 myotubes.
Furthermore, impaired AKT phosphorylation was associated with activation of caspases and PARP, reﬂecting
induction of apoptosis. Similar ﬁndings were detected in skeletal muscle of mice treated orally with
5 mg/kg/day simvastatin for 3 weeks. In conclusion, this study highlights the importance of the AKT/mTOR sig-
naling pathway in statin-induced myotoxicity and reveals potential drug targets for treatment of patients with
statin-associated myopathies.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibi-
tors) are currently the most often prescribed and the most effective
cholesterol-lowering drugs. They are generally well-tolerated but can
rarely be associatedwith potentially severe adverse reactions, particular-
ly on skeletal muscle [1,2]. Statin-associated muscle injuries vary from
mild myopathy to potentially lethal rhabdomyolysis, a condition charac-
terized by massive destruction of muscle ﬁbers and release of their con-
tents into the bloodstream [3,4]. While muscle pain affects up to 20% of
statin users [5], more severe adverse muscular reactions are much rarer
[1,2]. In a large study in theUSA, the incidence of rhabdomyolysis leading
to hospitalization was zero for pravastatin, approximately 0.5 per
10,000 person-years for simvastatin and atorvastatin and 5.3 perx; mTOR, mammalian target of
orkhead boxO;MuRF-1,muscle
rpS6, ribosomal protein S6; 4E-
ehyde 3-phosphate dehydroge-
thylbenzthiazoline sulfonate];
, mTOR complex 1; mTORC2,
oxicology, University Hospital,
61 265 4560.
henbühl).10,000 person-years for cerivastatin [6]. In combination with a ﬁbrate,
the incidence rose by a factor of 10 or more.
While a high exposure to statins is a clearly established risk factor for
statin-associatedmyopathy [1,2,7], the molecular mechanisms leading to
muscle damage, in particular rhabdomyolysis, in patients treated with
statins are less clear [3]. Different factors could play a role; for example
impairedmitochondrial function [8,9], inductionof skeletalmuscle break-
down due to increased expression of atrogin-1/MaFbx [10], reduction of
skeletal muscle protein synthesis [11], inhibition of small GTPases due
to impaired prenylation [12] and/or impaired creatine synthesis [13].
Previous work from our group suggested that simvastatin-induced
myotoxicity might be related to inhibition of the phosphorylation and
thereby activation of AKT [14]. As shown in Fig. 1, the AKT signaling path-
way is essential formuscle growthduring development and regeneration.
AKT functions as a key regulator of both protein synthesis and degrada-
tion by activating the protein kinase mammalian target of rapamycin
(mTOR) [15] and by inhibiting forkhead box O (FoxO) transcription fac-
tors [16]. Moreover, AKT is directly involved in the regulation of cell sur-
vival through the suppression of apoptosis by blocking the activation of
caspases [17].
Activation of mTOR by AKT leads to phosphorylation of the ribosomal
protein S6 kinase (S6K) at Thr 389,which phosphorylates and thereby ac-
tivates the ribosomal protein S6 (rpS6) [18]. Furthermore, activation of
FoxO
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Fig. 1. Schematic representation of the AKT/mTOR signaling pathway. Upon activation by hormones, cytokines or growth factors, AKT translocates to the plasma membrane and is
phosphorylated on Ser 473 and on Thr 308. Once activated, AKT phosphorylates downstreamcytosolic and nuclear effectors inducing protein synthesis and blocking apoptosis and protein
degradation.
1842 A. Bonifacio et al. / Biochimica et Biophysica Acta 1853 (2015) 1841–1849mTOR leads to phosphorylation of the eukaryotic translation initiation
factor 4E binding protein 1 (4E-BP1), thereby disrupting its interaction
with eIF4E and making eIF4E available for mRNA translation [19]. Im-
paired activation of mTOR is therefore expected to reduce protein
synthesis.
Forkheadmembers of theO class (FoxO) forma family of transcription
factors involved in protein breakdown and apoptosis. Several insults such
as apoptosis, oxidative stress and/or cytokine release activate FoxO3a by
dephosphorylation, which is followed by nuclear translocation of the de-
phosphorylated protein [20]. Activation of Foxo3a is associatedwithmus-
cle atrophy, since nuclear translocation of FoxO3a triggers the expression
of mediators of proteolysis such as muscle RING-ﬁnger protein-1 (MuRF-
1) and muscle atrophy F-box (atrogin-1/MaFbx) [21,22].
Taking into account our previous observations regarding the effect of
simvastatin on AKT activation [14] and the central role of AKT for skel-
etal muscle protein metabolism and integrity [15–17], the principle
aims of the current study were 1. to investigate whether inhibition of
the phosphorylation of AKT is speciﬁc for simvastatin or can also ob-
served for other statins, 2. to investigate the downstream effects of the
inhibition of AKT on target proteins involved in apoptosis, protein deg-
radation and protein synthesis, and 3. to demonstrate that these effects
cannot only be shown in vitro in cultured myotubes but also in vivo in
mice treated with simvastatin.
2. Materials and methods
2.1. Chemicals
Simvastatin lactone (Sigma-Aldrich, St. Louis, MO, USA) was con-
verted into the active acid following the protocol of Bogman et al. [23].We prepared stock solutions (10mMand 50mM) in dimethylsulfoxide
(DMSO) for simvastatin and in water for rosuvastatin and atorvastatin.
We stored them at −20 °C. All chemicals were supplied by Sigma-
Aldrich (St. Louis, MO, USA), except where indicated.
2.2. Cell lines and cell culture
C2C12 myoblasts were originally obtained from the American Type
Culture Collection (ATCC) and kindly provided by Novartis (Basel,
CH). We grew cells at 37 °C and 5% CO2 in a humidiﬁed cell culture in-
cubator and we passaged them using trypsin. We initially seeded
150,000 myoblasts per well in a 6-well plate, and grew them for
2 days in growth medium consisting of high glucose (4.5 g/L)
Dulbecco's Modiﬁed Eagle Medium (DMEM) containing GlutaMAX
(Invitrogen, Basel, Switzerland) and 10% heat-inactivated fetal bovine
serum (Gibco, Paisley, UK). Afterwards, we induced cell differentiation
using high glucose DMEM supplemented with 2% horse serum (Gibco,
Paisley, UK) for 3 days. A morphological analysis of the cell cultures
showed that 83±3% of the nuclei were located in tubes. Then,we incu-
bated the cell cultures in serum-free DMEM (Invitrogen, Basel,
Switzerland) for 24 h before the addition of the test compounds. Since
simvastatin had been dissolved in DMSO, we used control incubations
containing 0.1% DMSO. This DMSO concentration has been shown not
to be cytotoxic [24]. After 24 h treatment, we collected the cells to ex-
amine the expression of genes and activation of proteins of interest.
2.3. Animals
The animal studywas approved by the cantonal veterinary authority
(License 2659) and was performed in accordance with the guidelines
1843A. Bonifacio et al. / Biochimica et Biophysica Acta 1853 (2015) 1841–1849from Directive 2010/63/EU of the European Parliament on the protec-
tion of animals used for scientiﬁc purposes. Seven weeks old male
C57BL/6 mice were obtained from Charles River Laboratories (Sutzfeld,
Germany) and were housed under controlled conditions at a 12 h/
12 h light/dark cycle with free access to water and a standard pellet
chow. After 7 days of acclimatization, the mice were randomly divided
into two groups of eight animals. We treated the mice either with sim-
vastatin (5 mg/kg/day) dissolved in water (SMV group) or water (CTL
group) by oral gavage for 3 weeks. The body weight of the animals
and food intake were recorded every 2 days.
2.4. Sample collection
After 21 days of treatment,micewere anesthetizedwith an intraper-
itoneal application of ketamine (100 mg/kg) and xylazine (10 mg/kg).
Gastrocnemius muscle samples were frozen in liquid nitrogen immedi-
ately after excision. Since the tissue samples were obtained from living
animals (mice were anesthetized), the time between sampling and
freezing was only few seconds. Samples were kept at −80 °C until
analysis.
2.5. Cytotoxicity assay
Weused the ToxiLight BioAssay Kit (Lonza, Basel, Switzerland) to in-
vestigate the cytotoxicity of the compounds on C2C12 myotubes. The
release of adenylate kinase was measured according to the
manufacturer's manual using luminescence with a Tecan M200 Pro In-
ﬁnity plate reader (Männedorf, Switzerland).
2.6. Cell lysis and immunoblotting
After incubationwith different compounds, we homogenized C2C12
myotubes in Phosphosafe buffer (EMDMillipore, USA). Then,we centri-
fuged the samples at 1600 ×g for 10 min at 4 °C. We then collected the
supernatant and determined the protein content in each supernatant
using the BCA Protein Assay Kit (Pierce, Thermo Scientiﬁc, Rockford,
USA). Supernatants were applied on 4–12% Bis–Tris polyacrylamide
gels (Invitrogen, Basel, Switzerland) for protein separation and run
under reducing conditions. After separation, proteins were transferred
to polyvinylidendiﬂuoride membranes (EMD Millipore, Massachusetts,
USA).Weblocked themembraneswith 5%nonfat drymilk in phosphate
buffered saline (PBS) (Gibco, Paisley, UK) containing 0.1% Tween-20
(Sigma-Aldrich, MO, USA) (PBS-T) for 1 h at room temperature before
incubation overnight with the primary antibody (Cell Signaling Tech-
nology, USA) diluted 1:1000 in blocking buffer. The day after, we incu-
bated the blots for 1 h with the secondary antibody (Santa Cruz
Biotechnology, USA) diluted 1:2000 in 5% nonfat milk in PBS-T. Then,
we washed the membranes and developed the immunoreactive bands
using enhanced chemiluminescence (GE Healthcare, Buckinghamshire,
United Kingdom). Chemiluminescent imageswere scanned using anHP
Scanjet 8300 (Hewlett-Packard Co., Palo Alto, CA) and band intensities
of the scanned images were analyzed using the National Institutes of
Health Image J program (version 1.41). To correct for loading differ-
ences, the scanning units obtained for the test proteins were divided
by the scanning units obtained for either the respective total protein
or for housekeeping protein GAPDH.
The ELISA for the quantiﬁcation of S6K phosphorylation at T389was
obtained from Abcam, Cambridge, UK (p70S6K pT389 PhosphoTracer
ELISA Kit). The ELISA was performed exactly using the protocol of the
provider described in the protocol book.
2.7. Real-time polymerase chain reaction (RT-PCR)
We treated C2C12 myotubes with 10 μM and 50 μM of simvastatin,
rosuvastatin or atorvastatin for 24 h. Afterwards, mRNA was extracted
and puriﬁed using the Qiagen RNeasy mini extraction kit (Qiagen,Hombrechtikon, Switzerland). RNA concentration and integrity were
evaluated with the NanoDrop 2000 (Thermo Scientiﬁc, Wohlen,
Switzerland) and cDNA was synthesized from 10 μg RNA using the
Qiagen omniscript system. We performed the real-time PCR analysis
using SYBR green (Roche Diagnostics, Rotkreuz, Basel). We assessed
mRNA expression for genes associated with muscle atrophy using the
following primers. MAFbx: forward 5′AGTGAGGACCGGCTACTGTG3′
and reverse 5′GATCAAACGTTGCGAATCT3′. MuRF-1: forward 5′CCTG
CAGAGTGACCAAGGA3′ and reverse 5′GGCGTAGAGGGTGTCAAACT3′.
Real time PCR was performed using the ViiA7 software (Life technolo-
gies, Switzerland). We calculated relative quantities of speciﬁcally am-
pliﬁed cDNA with the comparative–threshold cycle method using
GAPDH as the housekeeping gene (forward 5′-CATGGCCTTCCGTGTTCC
TA-3′ and reverse 5′CCTGCTTCACCACCTTCTTGA-3′). Controls for non-
speciﬁc ampliﬁcation were run without reverse transcription.
2.8. Immunostaining and diameter measurement
To analyze changes inmyotube diameter,myotubeswere stained fol-
lowing the protocol of Minetti et al. [25]. Brieﬂy, myotubes were ﬁxed
with 4% PFA (Paraformaldehyde) and permeabilized with 0.2% Triton.
Nonspeciﬁc binding was blocked with goat serum (Gibco, Paisley, UK)
followed by incubation with anti-myosin heavy chain (anti-MHC)
(EMD Millipore, Massachusetts, USA) diluted 1:1000 in PBS and subse-
quently with Alexa ﬂuor 488 (Invitrogen, Basel, Switzerland) diluted
1:2000 in PBS. To measure diameters, we used CellInsight Technology
(Thermo scientiﬁc, Wohlen, Switzerland). The protein content of the
cells was determined as described in Section 2.6.
2.9. Apoptotic DNA fragmentation ELISA
Apoptosis-associated DNA fragmentation was quantiﬁed using the
cell death detection ELISA kit from Roche (Roche Applied Science,
Indianapolis, IN) by assessing the cytosolic histone-associated mono-
and oligo-nucleosomes. Brieﬂy, the extracted nuclei-free cytosolic frac-
tion was used as an antigen source in a sandwich ELISA with a primary
anti-histone mouse monoclonal antibody coated to the microtiter plate
and a second anti-DNA mouse monoclonal antibody coupled to peroxi-
dase. The amount of peroxidase retained in the immunocomplex was
determined photometrically after incubation with 2,2′-azino-di-[3-
ethylbenzthiazoline sulfonate] (ABTS) for 10 min at 20 °C. The change
in color was measured at 405 nm using a Tecan M200 Pro Inﬁnity
plate reader (Männedorf, Switzerland). Measurements were performed
in triplicate with all samples analyzed on the same microtiter plate in
the same setting. The OD readingwas normalized to the protein content
of the incubations.
2.10. Histological analysis of muscle tissue
Muscle samples were frozen in isopentane. Frozen sections were
stained with hematoxylin–eosin. H&E staining photographs were cap-
tured on an Olympus BX61 microscope (Olympus, Hamburg,
Germany). After staining, we selected randommuscle ﬁbers with a dis-
tinct cell membrane and we excluded elongated ﬁbers indicating an
oblique section. We employed Image J (version 1.41) software to mea-
sure muscle ﬁbers within 4 muscle cross-sections from 4 different
mice belonging to each group. We then calculated themean and the re-
spective SEM.
2.11. mRNA extraction of muscle tissue
mRNA was extracted and puriﬁed using the Quiagen RNeasy mini
extraction kit (Hombrechtikon, Switzerland) with a DNA digestion
step to ensure RNA quality. RNA quality was evaluated with the
NanoDrop 2000 (Thermo Scientiﬁc, Wohlen, Switzerland). We then
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Fig. 2. Cytotoxicity of statins in C2C12myotubes. C2C12myotubeswere exposed to 10 μM
or 50 μM simvastatin (SMV), rosuvastatin (RSV) or atorvastatin (ATV) for 24 h, and cyto-
toxicity was determined by adenylate kinase release using the Toxilight assay. Results
were normalized to the control incubations (DMSO 0.1%). Data represent the mean ±
SEM of three independent measurements carried out in triplicates. *P b 0.05 and
***P b 0.001 vs. DMSO control.
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of cDNA for quantitative RT-PCR performed as described above.
2.12. Immunoblotting of muscle tissue
Expression of components of the AKT signaling pathway and of apo-
ptosis pathways was checked by Western Blotting. We homogenized
frozen muscle samples with a Micro-Dismembrator S (Sartorius,
Göttingen, Germany) during 1 min at 2000 rpm. We then resuspended
the tissue powder in protein extraction reagent (T-PER, thermo Scientif-
ic,Wohlen, Switzerland) containing a protease inhibitor cocktail (Roche
AG, Basel, Switzerland), centrifuged at 9000 g at 4 °C for 5min, collected
the supernatant and determined protein levels.
Protein separation, blotting and quantiﬁcation of the separated pro-
teins were performed as the in vitro samples described above.
2.13. TUNEL assay
TUNEL (terminal deoxynucleotidyltransferase-mediated dUTP nick-
end labeling) staining of myonuclei positive for DNA strand breaks
was performed using a commercially available ﬂuorescence detection
kit (Life Technologies, Zug, Switzerland). Cross sections (10 μm) ofmus-
cles cut with a cryostat microtome were ﬁxed with 4% paraformalde-
hyde for 15 min and the ﬁxed sections were permeabilized with
2mg/mL proteinase K. The TUNEL reaction mixture containing terminal
deoxynucleotidyltransferase (TdT) and ﬂuorescein-labeled dUTP was
added to the sections in portions of 50 μL and then incubated for
60 min at 37 °C in a humidiﬁed chamber in the dark. After incubation,
the sections were rinsed three times in PBS for 1 min each. Following
embedding with ProLong diamond antifade mountant with DAPI (Life
Technologies, Zug, Switzerland), the sections were investigated with a
ﬂuorescence microscope (Olympus BX61, Germany; 40× objective).
2.14. Statistical methods
Data are presented as mean ± SEM. Statistical signiﬁcance
(*P b 0.05; **P b 0.01, ***P b 0.001)was determined using one-way anal-
ysis of variance (ANOVA) followed by Dunnett's multiple comparison
test. We performed all the statistical analyses using GraphPad Prism 5
(GraphPad Software, La Jolla, CA, US).
3. Results
3.1. Statins are toxic for C2C12 myotubes
The cytotoxicity of simvastatin, rosuvastatin, and atorvastatin for
C2C12 myotubes was determined after exposure for 24 h by measuring
the release of adenylate kinase (AK) (Fig. 2). Treatment with 10 μM or
50 μM simvastatin or atorvastatin was associated with cell death at both
concentrations. In contrast, rosuvastatin was cytotoxic only at 50 μM.
3.2. Statins affect the AKT signaling pathway in C2C12 myotubes
We have shown previously that simvastatin impairs AKT activation
in C2C12 myotubes [14]. In order to answer the question whether this
effect is speciﬁc for simvastatin or can be observed also for other statins,
we investigated the effects of three different statins on components of
AKT signaling pathway. Because the activity of the proteins involved
in the AKT signaling pathway is mainly regulated by phosphorylation,
we examined the changes in the phosphorylation status of the key pro-
teins and related them to the expression level of the respective total
protein (see Fig. 1). As shown in Fig. 3A, simvastatin and atorvastatin
signiﬁcantly inhibited the phosphorylation of AKT at S473 (but not at
T308), of 4E-BP1 at S65 and of FoxO3a at S253 and T32 in a
concentration-dependent way. Simvastatin signiﬁcantly inhibited the
phosphorylation of rpS6 at S235/236, whereas atorvastatin showedonly a numerical, but not a statistically signiﬁcant inhibition. The high
concentration of rosuvastatin showed a signiﬁcant 60% reduction of
AKT phosphorylation at S473 as well as a signiﬁcant reduction of
FoxO3a phosphorylation at T32. Phosphorylation of S6K at T389 was
signiﬁcantly (P b 0.05) inhibited by simvastatin (53 and 87% at 10 and
50 μM, respectively), by simvastatin (8 and 15% at 10 and 50 μM, respec-
tively) and by 50 μMrosuvastatin (5%) (determined by ELISA and there-
fore not shown in Fig. 3).
Since the AKT-associated phosphorylation of FoxO3a prevents the in-
duction of muscle-speciﬁc atrophy genes such as the E3 ubiquitin ligases
atrogin-1/MAFbx andMuRF-1 [22],we investigated themRNAexpression
of atrogin-1/MAFbx and MuRF-1. As shown in Fig. 3B and C, atrogin-1/
MAFbx and MuRF-1 mRNA expression were increased concentration-
dependently in response to simvastatin and atorvastatin and, to lesser ex-
tent, also in response to rosuvastatin. These results suggest that statins, in
particular simvastatin and atorvastatin, may promote skeletal muscle
atrophy.
3.3. Statins have atrophic effects on C2C12 myotubes
It iswell established that activation of theAKT/mTOR signaling path-
way is implicated in skeletalmuscle hypertrophy in vitro and in vivo [21,
26,27]. To determine whether statins could induce an atrophic pheno-
type due to the inhibition of AKT, we examined responses of myotubes
to 10 μM and 50 μM simvastatin, atorvastatin or rosuvastatin. C2C12
myotubes were treated with the different statins for 24 h and assayed
for changes in myotube diameter. As shown in Fig. 4A and B, treatment
with simvastatin and atorvastatin resulted in a distinct atrophic pheno-
type, with a concentration-dependent decrease inmyotube diameter. In
contrast, rosuvastatin did not signiﬁcantly reduce the diameter of
myotubes. In agreement with myotube atrophy, simvastatin and ator-
vastatin were both associated with a signiﬁcant decrease in the total
protein content of the myotubes, whereas rosuvastatin decreased the
protein content only numerically without reaching statistical signiﬁ-
cance (Fig. 4C).
3.4. Statins induce apoptosis of myotubes
It is well established that inhibition of the AKT signaling pathway is
associated with apoptosis [17,28]. We therefore analyzed whether the
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Fig. 3. Effect of statins on components of the AKT/mTOR pathway in C2C12 myotubes. C2C12 myotubes were cultured in serum-free medium for 24 h and then treated with 10 or 50 μM
simvastatin (SMV), rosuvastatin (RSV)or atorvastatin (ATV) for 24 h. 0.1%DMSOwasused as a negative control. A:Westernblot analysis of the expression of phosphorylatedAKT (P-AKT),
phosphorylated ribosomal protein S6 (P-rpS6), phosphorylated 4E-binding protein 1 (P-4E-BP1), phosphorylated Forkhead box protein O3a (P-FoxO3a) and the respective total proteins.
B. and C. mRNA expression of MAFbx and MuRF-1 after statin treatment was determined by real-time PCR. GAPDH was used as housekeeping gene. Data represent the mean ± SEM of
three to four independent experiments carried out in triplicates. **P b 0.01 and ***P b 0.001 vs. DMSO control.
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sis of C2C12 myotubes. Indeed, treatment of C2C12 myotubes with
10 μM or 50 μM simvastatin or atorvastatin for 24 h was associated
with increased expression of several markers of apoptosis, such as the
cleaved forms of caspase 9, caspase 3 and PARP (Fig. 5A). In contrast,
10 μM rosuvastatin was not associated with cleavage of the caspases
or of PARP, whereas 50 μM rosuvastatin caused a smaller increase in
markers of apoptosis than simvastatin or atorvastatin. In order to verify
that this increase in markers of apoptosis is associated with apoptosis,
we evaluated DNA fragmentation which is a feature of apoptotic cell
death. As expected, simvastatin and atorvastatin inducedDNA fragmen-
tation in a concentration-dependent fashion starting at 10 μM, while
rosuvastatin increased DNA fragmentation only at 50 μM (Fig. 5B).
3.5. Simvastatin impairs the AKT signaling pathway and induces apoptosis
in mice in vivo
To further conﬁrm the role of the AKT pathway in statin-
induced myotoxicity, we treated the mice orally with simvastatin
5mg/kg bodyweight/day for 21days.We then analyzed skeletalmuscle
proteins involved in the AKT pathway. Similar to the in vitro ﬁndings,
simvastatin signiﬁcantly inhibited the phosphorylation of AKT at S473
and FoxO3a at S253, resulting in up-regulation of mRNA of atrogin-1/
MAFbx, a gene involved in muscle atrophy (Fig. 6A and B). We then
analyzed whether the inhibition of the AKT signaling pathway by
simvastatin was linked to apoptosis in murine skeletal muscle. Indeed,treatment with simvastatin for 21 days induced the cleavage of caspases
9 and 3, which are markers of apoptosis (Fig. 6C). In addition, TUNEL
positive myonuclei, representing DNA strand breaks and indicating
apoptosis, could only be detected in the gastrocnemius of mice treated
with simvastatin and not in controlmice (Fig. 6D). Theseﬁndings demon-
strated that the results obtained in vitro are reproducible in mice in vivo.
3.6. Simvastatin reduces the skeletal muscle ﬁber area in mice
To investigatewhether inhibition of AKTby simvastatin could induce
muscle atrophy also in vivo in mice, we examined the area of myoﬁbers
in mice treated with simvastatin for 21 days. Indeed, treatment with
simvastatin resulted in a signiﬁcant reduction of the myoﬁber area
(Fig. 7). The results show that simvastatin can induce muscle ﬁber atro-
phy not only in vitro, but also in mice in vivo.
4. Discussion
The current investigations were based on a previous study from our
laboratory in which we showed that simvastatin interferes with AKT
phosphorylation in C2C12 myotubes, but not in HepG2 cells [14]. The
results of the current study conﬁrmand expand theseﬁndings in several
ways. First, we could demonstrate that the inhibition of AKT phosphor-
ylation in C2C12myotubes is not speciﬁc for simvastatin, but can be ob-
served also for the other statins investigated, particularly for the
lipophilic atorvastatin. Second,we could demonstrate the consequences
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way and for important cellular processes related to AKT signaling such
as skeletal muscle protein synthesis and breakdown as well as apopto-
sis. Third, we could show that these effects of statins are not only an
in vitro phenomenon, but can also be detected in mice treated with a
simvastatin dose which is comparable to the doses used in humans.
The fact that all statins investigated were cytotoxic and inhibited the
AKT signaling pathway (the more hydrophilic rosuvastatin to a lesser ex-
tent than the lipophilic simvastatin and atorvastatin) is compatible with
the assumption that the mechanism of AKT inhibition is associated with
themode of action of the statins, namely inhibition of cholesterol synthesis
at the level of hydroxymethylglutaryl-CoA (HMG)-CoA reductase. It has
been postulated that intermediates between HMG and cholesterol, in par-
ticular farnesyl-pyrophosphate and geranylgeranyl-pyrophosphate, which
are important for protein prenylation [12], can be diminished in skeletal
muscle of patients treated with statins to such an extent that myopathy
can occur [3]. This hypothesis is supported by the observation that the ad-
dition of mevalonate, but not of cholesterol, could at least partially pre-
vent myotoxicity associated with lovastatin in rabbits [29]. It is difﬁcult,
however, to explain by this mechanism why statins impair the AKT sig-
naling pathway. A possible explanation may be related to the observa-
tions that prenylation is important for the function of small GTPases
[12] and that statins can inhibit their prenylation [30]. Rab1, a prenylated
small GTPase, has been shown to stimulate AKT phosphorylation [31] and
to possibly be involved in statin-associated muscle damage [12,14]. Since
overexpression of Rab1 could not normalize AKT phosphorylation in
C2C12 myotubes exposed to simvastatin [14], the precise role of statin-
induced loss of Rab1 prenylation for impaired AKT activation is currently
not clear and needs further investigation.
A second possibility to explain the effect of statins on the AKT signal-
ing pathway is by the well-established mitochondrial toxicity of these
compounds [8,9,32,33]. By impairing the function of the mitochondrial
respiratory chain, statins decrease the skeletal muscle ATP and increase
the ADP content [34], leading to the activation of AMPK. AMPK activa-
tion is associated with impaired phosphorylation of AKT, as shown in
a recent study describing the toxicity of simvastatin cultured H9c2
cardiomyocytes and in mice in vivo [35].
Interestingly, all statins investigated impaired AKT phosphorylation
at S473, but not at T308 (Fig. 3A). AKT phosphorylation at S473 is per-
formed bymTORC2,whereasAKTphosphorylation at T308 is performed
by phosphoinositide-dependent kinase-1 (PDK1), a component of the
IgF-1 receptor/AKT pathway [36]. Taking into account that statins not
only impaired the activity of mTORC2, but also of mTORC1 (impaired
phosphorylation of S6K, rpS6 and 4E-BP1), a third possible mechanism
is impairment of mTOR, a component of both TORC1 and TORC2 [37]
by a so far not identiﬁed mechanism.
Independently of the mechanism leading to impaired AKT phos-
phorylation, the inhibition of the AKT signalingpathwayhad several im-
portant consequences on C2C12 cells and also on skeletal muscle of
mice treated with simvastatin. Statins that inhibited the phosphoryla-
tion of S6K, which impaired phosphorylation of the ribosomal protein
S6 (Fig. 3A) have an important role in mRNA translation and protein
synthesis [18]. Although we did not directly determine protein synthe-
sis by C2C12 myotubes in the current study, the observed reduction in
the protein content of C2C12 myotubes is compatible with impaired
protein synthesis, which is likely a consequence of impaired rpS6
phosphorylation.
In addition, AKT activation blocks protein degradation via the phos-
phorylation of FoxO3a, which impairs nuclear translocation of FoxO3a
and the subsequent expression of the muscle atrophy markers MuRF-1
and atrogin-1/MAFbx [22,26]. As expected in the case of impaired AKT
phosphorylation, we observed reduced phosphorylation of FoxO3a in
the presence of statins, which was associated with increased mRNA ex-
pression of MuRF-1 and atrogin-1/MAFbx (in mice treated with simva-
statin only the mRNA expression of atrogin-1/MAFbx was signiﬁcantly
increased). MuRF-1 and atrogin-1/MAFbx are associated with skeletalmuscle protein degradation, offering an additional explanation for the
observed decrease in the protein content of C2C12 myotubes and in
skeletal muscle atrophy observed in mice treated with simvastatin.
Statins are known to induce apoptosis in various cells types [8,9,35].
In our previous study in L6 cells (a rat skeletal muscle cell line) [8], we
postulated amitochondrial mechanisms for statin-associated apoptosis.
Similar ﬁndings were reported by Kwak et al. [9], who investigated the
effect of simvastatin in primary human myotubes. The current study
shows that statins can induce apoptosis in C2C12 myotubes and in
mice in vivo and indicates that statins can trigger apoptosis by inhibition
of theAKT signaling pathway. This interpretation is compatiblewith our
recent ﬁndings in cultured H9c2 cardiomyocytes [35] and with reports
about statin-induced apoptosis in cancer cells [38].
Interestingly, in the current study, we consistently observed a lower
toxicity of rosuvastatin compared to atorvastatin and simvastatin. In
agreement with this ﬁnding, in publications reporting skeletal muscle
adverse events for statins, it is generally agreed that lipophilic statins
such as simvastatin are more toxic than the more hydrophilic com-
pounds such as pravastatin [1,2,6]. Rosuvastatin, which is more hydro-
philic than simvastatin or atorvastatin, has a good safety record
regarding myotoxicity when used at the recommended dosage [39].
The results of the current study are in agreement with a previous
study from our laboratory showing that pravastatin was less toxic
than simvastatin and atorvastatin on cultured L6 cells and on isolated
rat skeletal muscle mitochondria [8]. Two possible explanations for
this ﬁnding are that hydrophilic statins have more difﬁculties to enter
cells than lipophilic compounds or that rosuvastatin is per se less toxic
for the AKT signaling pathway. The second possibility is less likely,
since rosuvastatin is the most potent statin currently on the market
and inhibition of HMG-CoA reductase is a likely toxicological mecha-
nism. Regarding the ﬁrst possibility, it is clearly established that differ-
ent organic anion transport proteins (OATP), which are responsible for
statin transport into the liver, are also expressed in skeletal muscle
[40] and are important for the transport of statins into skeletal muscle
[41]. At low concentrations, transport of both hydrophilic and lipophilic
statins into myocytes appears to be achieved mainly by OATPs [40]. At
the concentrations used in the current study, which may be reached in
the systemic circulation when transport of statins into the liver and/or
hepatic metabolism is blocked [41,42], diffusion may also play a role.
When diffusion becomes important, lipophilic statins may reach higher
intracellular concentrations than the hydrophilic compounds, possibly
explaining that simvastatin and atorvastatinweremore toxic in the cur-
rent studies than rosuvastatin.
Statin-associated rhabdomyolysis is a rare event, usually occurring
in patients treated with a therapeutic dose. Two well established risk
factors include a high systemic exposure [1] and underlying metabolic
muscle disease [43,44]. High systemic exposures in patients treated
with a therapeutic dose can result from inherited malfunction of the
transport mechanism into hepatocytes [7] or from drug-statin interac-
tions [42,45,46]. Regarding drug-statin interactions, mainly (but not ex-
clusively) the lipophilic statins are affected and the increase in the
systemic exposure can be substantial, leading to serum concentrations
in the low micromolar range [42]. The dependence of muscle toxicity
with statin exposure is clearly demonstrated also by the current studies
with C2C12 myotubes.5. Conclusions
The current study demonstrates that statins are cytotoxic and impair
AKT phosphorylation in C2C12myotubes and in skeletal muscle of mice
in vivo. The lipophilic simvastatin and atorvastatin showed a higher
in vitro toxicity than the hydrophilic rosuvastatin. Impaired phosphory-
lation of AKT was associated with myoﬁbrillar atrophy and apoptotic
cell death of C2C12 myotubes. Similar ﬁndings were also obtained in
skeletal muscle of mice treated with simvastatin. These ﬁndings may
1849A. Bonifacio et al. / Biochimica et Biophysica Acta 1853 (2015) 1841–1849have therapeutic implications, since activation of the AKT signaling
pathway may improve myopathy in patients treated with statins.
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